{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:15:04Z","timestamp":1788189304700,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Projects Coordination Unit of Tekirdag Namik Kemal University","award":["NKUBAP.10.GC.24.537"],"award-info":[{"award-number":["NKUBAP.10.GC.24.537"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer remains highly dependent on androgen receptor (AR) signaling, yet therapeutic escape often emerges through incomplete suppression of AR-driven transcription and activation of compensatory survival pathways. Here, we investigated whether a hyaluronic acid-coated selenium nanoparticle formulation loaded with apigenin (HA-SeNP-Api) could enhance the anti-tumor activity of apigenin in androgen-responsive LNCaP prostate cancer cells. Selenium nanoparticles were generated by reduction of sodium selenite with ascorbic acid, followed by apigenin loading and hyaluronic acid coating. After 72\u00a0h treatment, HA-SeNP-Api produced a consistent biological response across several measured endpoints among the tested groups. Apigenin screening identified 6.25 \u00b5M as a biologically active sub-IC50 working concentration. At this dose, the nanoformulation reduced AR and PSA mRNA expression to 0.27-fold and 0.42-fold, respectively, and lowered PSA protein to 10% of control. Total apoptosis increased to 44.30%, compared with 31.36% for selenium nanoparticles alone, 9.77% for apigenin, and 3.70% for enzalutamide. The formulation also increased p53 and p21 expression, reduced SOX2, OCT3\/4 and SLUG, and retained growth-inhibitory activity in 3D spheroids. These findings suggest that HA-SeNP-Api enhances the biological activity of apigenin under the tested in vitro conditions and modulates AR\/PSA-associated readouts, apoptosis-associated responses, and selected plasticity-associated transcripts in LNCaP cells.<\/jats:p>","DOI":"10.1038\/s41598-026-63769-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:53:10Z","timestamp":1784821990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanoparticle-enhanced apigenin suppresses androgen receptor signaling and cellular plasticity in LNCaP cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Sinan","family":"Vicil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riza","family":"Serttas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suat","family":"Erdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"63769_CR1","doi-asserted-by":"publisher","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front. Public. Health 10, 811044. https:\/\/doi.org\/10.3389\/fpubh.2022.811044 (2022).","journal-title":"Front. Public. Health"},{"key":"63769_CR2","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.3390\/cells9122653","volume":"9","author":"G Aurilio","year":"2020","unstructured":"Aurilio, G. et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells 9, 2653. https:\/\/doi.org\/10.3390\/cells9122653 (2020).","journal-title":"Cells"},{"key":"63769_CR3","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.18632\/oncotarget.12554","volume":"8","author":"DT Hoang","year":"2017","unstructured":"Hoang, D. T. et al. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: opportunities for therapeutic targeting from multiple angles. Oncotarget 8, 3724\u20133745. https:\/\/doi.org\/10.18632\/oncotarget.12554 (2017).","journal-title":"Oncotarget"},{"key":"63769_CR4","doi-asserted-by":"publisher","first-page":"a030437","DOI":"10.1101\/cshperspect.a030437","volume":"8","author":"DP Labb\u00e9","year":"2018","unstructured":"Labb\u00e9, D. P. & Brown, M. Transcriptional regulation in prostate cancer. Cold Spring Harb. Perspect. Med. 8, a030437. https:\/\/doi.org\/10.1101\/cshperspect.a030437 (2018).","journal-title":"Cold Spring Harb Perspect. Med."},{"key":"63769_CR5","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.3390\/cancers15235612","volume":"15","author":"V Baumgartner","year":"2023","unstructured":"Baumgartner, V., Schaer, D. J., Eberli, D. & Salemi, S. Targeting metabolic vulnerabilities to overcome prostate cancer resistance: dual therapy with apalutamide and complex I inhibition. Cancers 15, 5612. https:\/\/doi.org\/10.3390\/cancers15235612 (2023).","journal-title":"Cancers"},{"key":"63769_CR6","doi-asserted-by":"publisher","first-page":"580617","DOI":"10.3389\/fonc.2020.580617","volume":"10","author":"T Uo","year":"2020","unstructured":"Uo, T., Sprenger, C. C. T. & Plymate, S. R. Androgen receptor signaling and metabolic and cellular plasticity during progression to castration resistant prostate cancer. Front. Oncol. 10, 580617. https:\/\/doi.org\/10.3389\/fonc.2020.580617 (2020).","journal-title":"Front. Oncol."},{"key":"63769_CR7","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1210\/me.2004-0445","volume":"19","author":"S Gao","year":"2005","unstructured":"Gao, S. et al. The androgen receptor directly targets the cellular Fas\/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol. Endocrinol. 19, 1792\u20131802. https:\/\/doi.org\/10.1210\/me.2004-0445 (2005).","journal-title":"Mol. Endocrinol."},{"key":"63769_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3892\/ijo.28.1.245","volume":"28","author":"S Lu","year":"2006","unstructured":"Lu, S., Ren, C., Liu, Y. & Epner, D. E. PI3K-Akt signaling is involved in the regulation of p21WAF\/CIP expression and androgen-independent growth in prostate cancer cells. Int. J. Oncol. 28, 245\u2013251. https:\/\/doi.org\/10.3892\/ijo.28.1.245 (2006).","journal-title":"Int. J. Oncol."},{"key":"63769_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/pros.20844","volume":"68","author":"KA Raclaw","year":"2008","unstructured":"Raclaw, K. A., Heemers, H. V., Kidd, E. M., Dehm, S. M. & Tindall, D. J. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate 68, 1696\u20131706. https:\/\/doi.org\/10.1002\/pros.20844 (2008).","journal-title":"Prostate"},{"key":"63769_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2016.08.019","volume":"162","author":"S Erdogan","year":"2016","unstructured":"Erdogan, S. et al. The flavonoid apigenin reduces prostate cancer CD44\u2009+\u2009stem cell survival and migration through PI3K\/Akt\/NF-\u03baB signaling. Life Sci. 162, 77\u201386. https:\/\/doi.org\/10.1016\/j.lfs.2016.08.019 (2016).","journal-title":"Life Sci."},{"key":"63769_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s11095-010-0089-7","volume":"27","author":"S Shukla","year":"2010","unstructured":"Shukla, S. & Gupta, S. Apigenin: a promising molecule for cancer prevention. Pharm. Res. 27, 962\u2013978. https:\/\/doi.org\/10.1007\/s11095-010-0089-7 (2010).","journal-title":"Pharm. Res."},{"key":"63769_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/carcin\/bgt316","volume":"35","author":"S Shukla","year":"2014","unstructured":"Shukla, S. et al. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K\/Akt\/FoxO pathway. Carcinogenesis 35, 452\u2013460. https:\/\/doi.org\/10.1093\/carcin\/bgt316 (2014).","journal-title":"Carcinogenesis"},{"key":"63769_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.31665\/jfb.2019.8204","volume":"8","author":"F Shahidi","year":"2019","unstructured":"Shahidi, F., Ramakrishnan, V. V. & Oh, W. Y. Bioavailability and metabolism of food bioactives and their health effects: a review. J. Food Bioact. 8, 6\u201341. https:\/\/doi.org\/10.31665\/jfb.2019.8204 (2019).","journal-title":"J. Food Bioact"},{"key":"63769_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.22037\/IJPR.2019.2347","volume":"18","author":"Y Huang","year":"2019","unstructured":"Huang, Y. et al. Enhanced solubility and bioavailability of apigenin via preparation of solid dispersions of mesoporous silica nanoparticles. Iran. J. Pharm. Res. 18, 168\u2013182. https:\/\/doi.org\/10.22037\/IJPR.2019.2347 (2019).","journal-title":"Iran. J. Pharm. Res."},{"key":"63769_CR15","doi-asserted-by":"publisher","unstructured":"Uz, Y. H. & Erdogan, S. Enhancing the therapeutic index of bioactive compounds through novel delivery systems. Balkan Med. J. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2026.2026.270326","DOI":"10.4274\/balkanmedj.galenos.2026.2026.270326"},{"key":"63769_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3390\/cells10040758","volume":"10","author":"K Chun","year":"2021","unstructured":"Chun, K., Kim, D. & Surh, Y. J. Role of reductive versus oxidative stress in tumor progression and anticancer drug resistance. Cells 10, 758. https:\/\/doi.org\/10.3390\/cells10040758 (2021).","journal-title":"Cells"},{"key":"63769_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4274\/balkanmedj.galenos.2025.2025.130825","volume":"42","author":"\u0130 Gulcin","year":"2025","unstructured":"Gulcin, \u0130. Antioxidants: current summary. Balkan Med. J. 42, 388\u2013392. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2025.2025.130825 (2025).","journal-title":"Balkan Med. J."},{"key":"63769_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/1535-7163.MCT-05-0124","volume":"4","author":"Y Dong","year":"2005","unstructured":"Dong, Y., Zhang, H., Gao, A. C., Marshall, J. R. & Ip, C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol. Cancer Ther. 4, 1047\u20131055. https:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0124 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"63769_CR19","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1016\/j.biomaterials.2011.05.032","volume":"32","author":"L Kong","year":"2011","unstructured":"Kong, L. et al. The suppression of prostate LNCaP cancer cells growth by selenium nanoparticles through Akt\/Mdm2\/AR controlled apoptosis. Biomaterials 32, 6515\u20136522. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.05.032 (2011).","journal-title":"Biomaterials"},{"key":"63769_CR20","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3389\/fonc.2019.01541","volume":"9","author":"P Sonkusre","year":"2020","unstructured":"Sonkusre, P. Specificity of biogenic selenium nanoparticles for prostate cancer therapy with reduced risk of toxicity: an in vitro and in vivo study. Front. Oncol. 9, 1541. https:\/\/doi.org\/10.3389\/fonc.2019.01541 (2020).","journal-title":"Front. Oncol."},{"key":"63769_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.30827\/ars.v63i4.25208","volume":"63","author":"G Gupta","year":"2022","unstructured":"Gupta, G. et al. Recent advancements in cancer targeting therapy with hyaluronic acid as a potential adjuvant. Ars Pharm. 63, 387\u2013401. https:\/\/doi.org\/10.30827\/ars.v63i4.25208 (2022).","journal-title":"Ars Pharm."},{"key":"63769_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1021\/mp800024g","volume":"5","author":"VM Platt","year":"2008","unstructured":"Platt, V. M. & Szoka, F. C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 5, 474\u2013486. https:\/\/doi.org\/10.1021\/mp800024g (2008).","journal-title":"Mol. Pharm."},{"key":"63769_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen, C., Zhao, S., Karnad, A. B. & Freeman, J. W. The biology and role of CD44 in cancer progression: therapeutic implications. J. Hematol. Oncol. 11, 64. https:\/\/doi.org\/10.1186\/s13045-018-0605-5 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"63769_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1101\/gad.319889.118","volume":"33","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 33, 166\u2013179. https:\/\/doi.org\/10.1101\/gad.319889.118 (2019).","journal-title":"Genes Dev."},{"key":"63769_CR25","doi-asserted-by":"publisher","first-page":"15812","DOI":"10.3390\/ijms242115812","volume":"24","author":"N Cirillo","year":"2023","unstructured":"Cirillo, N. The hyaluronan\/CD44 axis: a double-edged sword in cancer. Int. J. Mol. Sci. 24, 15812. https:\/\/doi.org\/10.3390\/ijms242115812 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"63769_CR26","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/1078-0432.CCR-09-0479","volume":"15","author":"BP Toole","year":"2009","unstructured":"Toole, B. P. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin. Cancer Res. 15, 7462\u20137468. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0479 (2009).","journal-title":"Clin. Cancer Res."},{"key":"63769_CR27","doi-asserted-by":"publisher","first-page":"17946","DOI":"10.1039\/D5RA09291D","volume":"16","author":"S Vicil","year":"2026","unstructured":"Vicil, S., Serttas, R. & Erdogan, S. Targeted elimination of CD44\u2009+\u2009prostate cancer stem cells using hyaluronic acid-coated selenium nanoparticles co-loaded with apigenin. RSC Adv. 16, 17946\u201317962. https:\/\/doi.org\/10.1039\/D5RA09291D (2026).","journal-title":"RSC Adv."},{"key":"63769_CR28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s10637-019-00774-8","volume":"38","author":"S Erdogan","year":"2019","unstructured":"Erdogan, S. et al. Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-\u03baB. Invest. New. Drugs. 38, 246\u2013263. https:\/\/doi.org\/10.1007\/s10637-019-00774-8 (2019).","journal-title":"Invest. New. Drugs"},{"key":"63769_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.32471\/exp-oncology.2312-8852.vol-43-no-2.16096","volume":"43","author":"A Ayyildiz","year":"2021","unstructured":"Ayyildiz, A., Koc, H., Turkekul, K. & Erdogan, S. Co-administration of apigenin with doxorubicin enhances anti-migration and antiproliferative effects via PI3K\/PTEN\/AKT pathway in prostate cancer cells. Exp. Oncol. 43, 125\u2013134. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-43-no-2.16096 (2021).","journal-title":"Exp. Oncol."},{"key":"63769_CR30","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1021\/acs.biomac.8b00783","volume":"19","author":"A Gamarra","year":"2018","unstructured":"Gamarra, A., Mu\u00f1oz-Guerra, S., de Ilarduya, A. M., Th\u00e9rien-Aubin, H. & Landfester, K. Comblike ionic complexes of hyaluronic acid and alkanoylcholine surfactants as a platform for drug delivery systems. Biomacromolecules 19, 3669\u20133678. https:\/\/doi.org\/10.1021\/acs.biomac.8b00783 (2018).","journal-title":"Biomacromolecules"},{"key":"63769_CR31","doi-asserted-by":"publisher","first-page":"4553","DOI":"10.2174\/0929867325666180601101859","volume":"25","author":"J Schubert","year":"2018","unstructured":"Schubert, J. & Chanana, M. Coating matters: review on colloidal stability of nanoparticles with biocompatible coatings in biological media, living cells and organisms. Curr. Med. Chem. 25, 4553\u20134586. https:\/\/doi.org\/10.2174\/0929867325666180601101859 (2018).","journal-title":"Curr. Med. Chem."},{"key":"63769_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcancer.2015.03.001","volume":"35","author":"RM Mohammad","year":"2015","unstructured":"Mohammad, R. M. et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 35, 78\u2013S103. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.001 (2015).","journal-title":"Semin Cancer Biol."},{"key":"63769_CR33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","volume":"282","author":"F Bunz","year":"1998","unstructured":"Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497\u20131501. https:\/\/doi.org\/10.1126\/science.282.5393.1497 (1998).","journal-title":"Science"},{"key":"63769_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9, 400\u2013414. https:\/\/doi.org\/10.1038\/nrc2657 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"63769_CR35","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/cancers11091220","volume":"11","author":"NN Kreis","year":"2019","unstructured":"Kreis, N. N., Louwen, F. & Yuan, J. The multifaceted p21 (Cip1\/Waf1\/CDKN1A) in cell differentiation, migration and cancer therapy. Cancers 11, 1220. https:\/\/doi.org\/10.3390\/cancers11091220 (2019).","journal-title":"Cancers"},{"key":"63769_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12964-017-0206-x","volume":"15","author":"N Ferrari","year":"2017","unstructured":"Ferrari, N. et al. Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer. Cell. Commun. Signal. 15, 51. https:\/\/doi.org\/10.1186\/s12964-017-0206-x (2017).","journal-title":"Cell. Commun. Signal."},{"key":"63769_CR37","doi-asserted-by":"publisher","first-page":"160","DOI":"10.15430\/jcp.2023.28.4.160","volume":"28","author":"K Turkekul","year":"2023","unstructured":"Turkekul, K. & Erdogan, S. Potent suppression of prostate cancer cell growth and eradication of cancer stem cells by CD44-targeted nanoliposome-quercetin nanoparticles. J. Cancer Prev. 28, 160\u2013170. https:\/\/doi.org\/10.15430\/jcp.2023.28.4.160 (2023).","journal-title":"J. Cancer Prev."},{"key":"63769_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.biopha.2017.01.056","volume":"88","author":"S Erdogan","year":"2017","unstructured":"Erdogan, S., Turkekul, K., Serttas, R. & Erdogan, Z. The natural flavonoid apigenin sensitizes human CD44\u2009+\u2009prostate cancer stem cells to cisplatin therapy. Biomed. Pharmacother. 88, 210\u2013217. https:\/\/doi.org\/10.1016\/j.biopha.2017.01.056 (2017).","journal-title":"Biomed. Pharmacother"},{"key":"63769_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tips.2016.03.003","volume":"37","author":"J Kroon","year":"2016","unstructured":"Kroon, J., Kooijman, S., Cho, N., Storm, G. & van der Pluijm, G. Improving taxane-based chemotherapy in castration-resistant prostate cancer. Trends Pharmacol. Sci. 37, 451\u2013462. https:\/\/doi.org\/10.1016\/j.tips.2016.03.003 (2016).","journal-title":"Trends Pharmacol. Sci."},{"key":"63769_CR40","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.3390\/molecules28227565","volume":"28","author":"B Yang","year":"2023","unstructured":"Yang, B. et al. HA-coated PLGA nanoparticles loaded with apigenin for colon cancer with high expression of CD44. Molecules 28, 7565. https:\/\/doi.org\/10.3390\/molecules28227565 (2023).","journal-title":"Molecules"},{"key":"63769_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12896-024-00855-4","volume":"24","author":"M Eydelkhani","year":"2024","unstructured":"Eydelkhani, M., Kiabi, S. & Nowruzi, B. In vitro assessment of the effect of magnetic fields on efficacy of biosynthesized selenium nanoparticles by Alborzia kermanshahica. BMC Biotechnol. 24, 27. https:\/\/doi.org\/10.1186\/s12896-024-00855-4 (2024).","journal-title":"BMC Biotechnol."},{"key":"63769_CR42","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/nu15143136","volume":"15","author":"\u00cdRS Vieira","year":"2023","unstructured":"Vieira, \u00cd. R. S., Tessaro, L., Lima, A. K. O., Velloso, I. P. S. & Conte-J\u00fanior, C. A. Recent progress in nanotechnology improving the therapeutic potential of polyphenols for cancer. Nutrients 15, 3136. https:\/\/doi.org\/10.3390\/nu15143136 (2023).","journal-title":"Nutrients"},{"key":"63769_CR43","doi-asserted-by":"publisher","first-page":"681477","DOI":"10.3389\/fphar.2021.681477","volume":"12","author":"EF DeRango-Adem","year":"2021","unstructured":"DeRango-Adem, E. F. & Blay, J. Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers? Front. Pharmacol. 12, 681477. https:\/\/doi.org\/10.3389\/fphar.2021.681477 (2021).","journal-title":"Front. Pharmacol."},{"key":"63769_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.32604\/or.2023.042228","volume":"32","author":"A Wahi","year":"2023","unstructured":"Wahi, A. et al. Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment. Oncol. Res. 32, 19\u201342. https:\/\/doi.org\/10.32604\/or.2023.042228 (2023).","journal-title":"Oncol. Res."},{"key":"63769_CR45","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1080\/24701556.2017.1357611","volume":"47","author":"S Gangadoo","year":"2017","unstructured":"Gangadoo, S., Stanley, D., Hughes, R. J., Moore, R. J. & Chapman, J. The synthesis and characterisation of highly stable and reproducible selenium nanoparticles. Inorg. Nano-Met Chem. 47, 1568\u20131576. https:\/\/doi.org\/10.1080\/24701556.2017.1357611 (2017).","journal-title":"Inorg. Nano-Met Chem."},{"key":"63769_CR46","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.2147\/IJN.S129958","volume":"12","author":"K Bai","year":"2017","unstructured":"Bai, K., Hong, B., He, J., Hong, Z. & Tan, R. Preparation and antioxidant properties of selenium nanoparticles-loaded chitosan microspheres. Int. J. Nanomed. 12, 4527\u20134539. https:\/\/doi.org\/10.2147\/IJN.S129958 (2017).","journal-title":"Int. J. Nanomed."},{"key":"63769_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jddst.2018.11.013","volume":"49","author":"S Mahmoudi","year":"2019","unstructured":"Mahmoudi, S. et al. Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. J. Drug Deliv Sci. Technol. 49, 268\u2013276. https:\/\/doi.org\/10.1016\/j.jddst.2018.11.013 (2019).","journal-title":"J. Drug Deliv Sci. Technol."},{"key":"63769_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.diff.2017.08.005","volume":"97","author":"D McLean","year":"2017","unstructured":"McLean, D., Strand, D. W. & Ricke, W. A. Prostate cancer xenografts and hormone induced prostate carcinogenesis. Differentiation 97, 23\u201330. https:\/\/doi.org\/10.1016\/j.diff.2017.08.005 (2017).","journal-title":"Differentiation"},{"key":"63769_CR49","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12859-020-03696-y","volume":"21","author":"MT Ganger","year":"2020","unstructured":"Ganger, M. T., Dietz, G. D., Headley, P. & Ewing, S. J. Application of the common base method to regression and analysis of covariance (ANCOVA) in qPCR experiments and subsequent relative expression calculation. BMC Bioinform. 21, 423. https:\/\/doi.org\/10.1186\/s12859-020-03696-y (2020).","journal-title":"BMC Bioinform."},{"key":"63769_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.taap.2017.11.006","volume":"338","author":"ER Elkin","year":"2017","unstructured":"Elkin, E. R., Harris, S. M. & Loch-Caruso, R. Trichloroethylene metabolite S-(1,2-dichlorovinyl)-L-cysteine induces lipid peroxidation-associated apoptosis via the intrinsic and extrinsic apoptosis pathways in a first-trimester placental cell line. Toxicol. Appl. Pharmacol. 338, 30\u201342. https:\/\/doi.org\/10.1016\/j.taap.2017.11.006 (2017).","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63769-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63769-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:25:08Z","timestamp":1788186308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-63769-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["63769"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-63769-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"25 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used commercially available human cell lines obtained from the American Type Culture Collection (LNCaP and ARPE19; ATCC, Manassas, VA, USA). No primary human samples, patient-derived materials, or animal experiments were used in this work; therefore, no institutional ethical approval or informed consent was required.","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27273"}}